Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Yatharth Hospital shares fall up to 6% after Q4 margin narrows despite strong topline growth
Yatharth Hospital shares declined 8% to hit an intraday low of ₹792.85 apiece after reporting their fourth quarter earnings. The stock was trading 5% lower at ₹819 apiece at 2.20 pm. It has risen 9.11% in the past month and 21.4% this year, so far.
Blue Jet Healthcare Q4 Results: Stock gains 10% despite weak earnings; Board approves fund raise
For the March quarter, Blue Jet Healthcare's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) fell 49% to ₹71 crore from ₹140 crore a year ago, while EBITDA margin contracted sharply to 30.3% from 41%. Yet, the stock was up 10%.
Divi's Labs slips 3% on margin worries; analysts positive on growth outlook
In the March quarter, Divi's Laboratories reported net profit at ₹751 crore, as compared to ₹662 crore a year ago, up 13.4 per cent year-on-year (Y-o-Y)
Sun Pharma Shares In Focus As Motilal Oswal Retains Bullish Call After Q4 — Check Target Price, Upside
Sun Pharma delivered in-line revenue in Q4, whereas Ebitda/PAT came in lower than expected, dragged down by higher marketing spending and lower milestone income.
Retail health premium growth rises to 31% YoY in April 2026, anchoring non-life insurance sector: Kotak Institutional Securities
Indian non-life insurance saw robust growth in April 2026. Retail health premiums surged 31 percent year-on-year. Motor insurance also performed well. Private players and standalone health insurers are gaining market share from public sector companies. Commercial lines faced challenges, though marine and engineering segments showed resilience. This indicates a dynamic shift in the insurance landscape.
Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
Sun Pharma's US formulations sales fell 1.1% from last year to $459 million during the March quarter. For the full year, the growth was a negative 0.9%.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 22 May 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 22 May 2026Mint
Max Healthcare Q4 results: Cons PAT grows 7% YoY to Rs 342 crore, revenue rises 12%
Max Healthcare Q4FY26 consolidated PAT grew 7% YoY, and revenue increased 12%. Network EBITDA rose 8%. Max Lab and Max@Home saw strong double-digit growth. The company also recommended a final dividend of Rs 2 per equity share for the year.
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is anticipated from capacity expansions and new product lines. The company's contract development and manufacturing business is also expanding. Investors are watching Gland Pharma's growth prospects.
Apollo Hospitals FY26 profit jumps 34% to Rs 1,942 crore on growth across core businesses
Apollo Hospitals announced robust financial results for the fourth quarter and the full fiscal year 2026. Consolidated revenue and net profit saw significant year-on-year increases. Growth was fueled by its healthcare services, diagnostics, and retail health segments. The company is expanding its bed capacity and focusing on underserved markets.
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?
Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's performance and future prospects.
Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside — Check Revised Target Price
The current valuation provides limited upside and hence, Motilal Oswal has maintained Neutral rating on Zydus Lifesciences.